Here is What Analysts Have to Say About Hinge Health (HNGE)

Hinge Health (NYSE:HNGE) is one of the most promising mid-cap healthcare stocks under $50.

On December 19, the consensus ratings indicate a strong bullish stance towards Hinge Health (NYSE:HNGE). All 12 analysts covering the stock have assigned Buy ratings, which reflect favorably upon its prospects. The resulting consensus 1-year average price target for the stock is $67.53, which offers a lucrative 42.9% upside from the current level.

Romaset/Shutterstock.com

On December 12, Citizens reiterated its bullish stance on Hinge Health (NYSE:HNGE). The firm assigned a Buy rating to the stock, with a target price of $65 a share. This estimate offered a 38% upside to investors from the prevailing levels.

The firm’s positive sentiment is driven by Hinge Health’s (NYSE:HNGE) strong competitive position in the market. It is based on their strong ties with the top 5 national health plans and also the three most prominent pharmacy benefit managers (PBMs) across the U.S.

According to Citizens, Hinge Health’s (NYSE:HNGE) already established links within the healthcare landscape will prove to be the key enablers for future growth opportunities within this space. Being a leading player within the digital musculoskeletal (MSK) market, the company still has immense potential to grow.

Hinge Health (NYSE:HNGE) leverages an AI-enabled care model to automate the delivery of healthcare services. The company delivers customized, drug-free pain relief to users through health plans devised by physical therapists. They address musculoskeletal conditions of patients through an FDA-approved wearable device that is user-friendly and cost-efficient.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.